MSD Brazil, Avenida Chucri Zaidan, 296-11º Andar, Edif. Torre Z Vila Cordeiro, São Paulo, SP, CEP: 04583-110, Brazil.
IQVIA Brazil, São Paulo, Brazil.
Sci Rep. 2023 Sep 22;13(1):15785. doi: 10.1038/s41598-023-43131-9.
In Brazil, data on the management of triple negative breast cancer (TNBC) as well as the burden of the disease in terms of health care resources utilization (HCRU) are scarce. To characterize the treatment patterns and HCRU associated with the management of Brazilian TNBC patients from the perspective of the private healthcare setting. Patients with at least one claim related to ICD-10 C50 from January 2012 until December 2017, and at least one claim for breast cancer treatment were assessed from a private claims database and classified as early and locally advanced, or metastatic. All patients with hormone and/or targeted therapy were excluded. Three thousand and four patients were identified, of which 82.8% were diagnosed in early and locally advanced stages. For early and locally advanced TNBC patients, 75.3% were treated in an adjuvant setting, mainly with anthracycline regimes. For mTNBC patients, bevacizumab regimens were the main treatment prescribed. More than 48% of mTNBC patients were switched to a second line of treatment. HCRU was higher for mTNBC patients when compared to early and locally advanced patients, with higher costs for metastatic disease management. The treatment setting has little influence on the HCRU pattern or the cost of disease management. The highest burden of disease was observed for metastatic management.
在巴西，关于三阴性乳腺癌（TNBC）的管理数据以及医疗资源利用（HCRU）方面的疾病负担数据都很匮乏。本研究旨在从私立医疗机构的角度，描述巴西 TNBC 患者的治疗模式和 HCRU。从一个私立报销数据库中筛选出至少有一条 ICD-10 C50 相关的索赔记录且至少有一条乳腺癌治疗相关的索赔记录的患者，并将其分类为早期和局部晚期，或转移性。所有接受激素和/或靶向治疗的患者均被排除在外。共纳入了 3400 名患者，其中 82.8%的患者被诊断为早期和局部晚期。对于早期和局部晚期 TNBC 患者，75.3%的患者接受辅助治疗，主要采用蒽环类药物治疗方案。对于转移性 TNBC 患者，贝伐珠单抗方案是主要的治疗方案。超过 48%的转移性 TNBC 患者需要转换二线治疗。与早期和局部晚期患者相比，转移性 TNBC 患者的 HCRU 更高，转移性疾病管理的成本也更高。转移性疾病管理的负担最大。
